Other connections that might prove useful. Elan's Chairman and board member.
Robert Graham, who is now Chairman of Elan, and former high exec. at GSK, has another person at Elan, that has an interesting background. He is Andrew von Eschenbach, now an Elan director. If he sounds familiar, he should. He was Head of the FDA from 2005-09. Some of you may remember his involvement in the delay of DNDN's Provenge treatment for Prostate Cancer, that was hijacked when it was first delayed a few years and then only allowed later-stage use, when it was approved.
Irregardless, he has connections in the industry and the FDA which might prove useful, particularly if a company he was looking to buy was looking for an approval, like NCE for Vascepa, as an example. He probably knows a few at the patent office, as well. I have to think there is a lot of talk between them and JZ about the price.